% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Miglis:163375,
      author       = {Miglis, Mitchell G and Adler, Charles H and Antelmi, Elena
                      and Arnaldi, Dario and Baldelli, Luca and Boeve, Bradley F
                      and Cesari, Matteo and Dall'Antonia, Irene and Diederich,
                      Nico J and Doppler, Kathrin and Dušek, Petr and Ferri,
                      Raffaele and Gagnon, Jean-François and Gan-Or, Ziv and
                      Hermann, Wiebke and Högl, Birgit and Hu, Michele T and
                      Iranzo, Alex and Janzen, Annette and Kuzkina, Anastasia and
                      Lee, Jee-Young and Leenders, Klaus L and Lewis, Simon J G
                      and Liguori, Claudio and Liu, Jun and Lo, Christine and
                      Ehgoetz Martens, Kaylena A and Nepozitek, Jiri and Plazzi,
                      Giuseppe and Provini, Federica and Puligheddu, Monica and
                      Rolinski, Michal and Rusz, Jan and Stefani, Ambra and
                      Summers, Rebekah L S and Yoo, Dallah and Zitser, Jennifer
                      and Oertel, Wolfgang H},
      title        = {{B}iomarkers of conversion to α-synucleinopathy in
                      isolated rapid-eye-movement sleep behaviour disorder},
      journal      = {The lancet / Neurology},
      volume       = {20},
      number       = {8},
      issn         = {1474-4422},
      address      = {London},
      publisher    = {Lancet Publ. Group},
      reportid     = {DZNE-2022-00138},
      pages        = {671 - 684},
      year         = {2021},
      abstract     = {Patients with isolated rapid-eye-movement sleep behaviour
                      disorder (RBD) are commonly regarded as being in the early
                      stages of a progressive neurodegenerative disease involving
                      α-synuclein pathology, such as Parkinson's disease,
                      dementia with Lewy bodies, or multiple system atrophy.
                      Abnormal α-synuclein deposition occurs early in the
                      neurodegenerative process across the central and peripheral
                      nervous systems and might precede the appearance of motor
                      symptoms and cognitive decline by several decades. These
                      findings provide the rationale to develop reliable
                      biomarkers that can better predict conversion to clinically
                      manifest α-synucleinopathies. In addition, biomarkers of
                      disease progression will be essential to monitor treatment
                      response once disease-modifying therapies become available,
                      and biomarkers of disease subtype will be essential to
                      enable prediction of which subtype of α-synucleinopathy
                      patients with isolated RBD might develop.},
      subtyp        = {Review Article},
      keywords     = {Biomarkers / Disease Progression / Humans / Prognosis / REM
                      Sleep Behavior Disorder: complications / REM Sleep Behavior
                      Disorder: diagnosis / Synucleinopathies: diagnosis /
                      Synucleinopathies: etiology / alpha-Synuclein},
      cin          = {AG Teipel},
      ddc          = {610},
      cid          = {I:(DE-2719)1510100},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pmc          = {pmc:PMC8600613},
      pubmed       = {pmid:34302789},
      doi          = {10.1016/S1474-4422(21)00176-9},
      url          = {https://pub.dzne.de/record/163375},
}